Eight-year follow-up of a child with a GH/prolactin-secreting adenoma: Efficacy of pegvisomant therapy

Hormone Research in Paediatrics

Volumn 73, Issue 1, 2010, Pages 74-79

  Bergamaschi, S ^a   Ronchi, C L ^a   Giavoli, C ^a   Ferrante, E ^a   Verrua, E ^a   Ferrari, D I ^a   Lania, A ^a   Rusconi, R ^a   Spada, A ^a   Beck Peccoz, P ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Gigantism; Growth hormone; Insulin like growth factor I; Pegvisomant; Pituitary adenoma

Indexed keywords

CABERGOLINE; GROWTH HORMONE; OCTREOTIDE; PEGVISOMANT; PROLACTIN; SOMATOMEDIN C;

ADRENAL FUNCTION; ARTICLE; BONE AGE; CANCER SURGERY; CASE REPORT; CHILD; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GIGANTISM; GONAD FUNCTION; GROWTH HORMONE SECRETING ADENOMA; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRESCHOOL CHILD; PRIORITY JOURNAL; PROLACTINOMA; THYROID FUNCTION;

ADENOMA; CHILD, PRESCHOOL; FEMALE; FOLLOW-UP STUDIES; GIGANTISM; GROWTH HORMONE-SECRETING PITUITARY ADENOMA; HORMONE ANTAGONISTS; HUMAN GROWTH HORMONE; HUMANS; PITUITARY NEOPLASMS; PROLACTINOMA; TREATMENT OUTCOME;

EID: 77951446342     PISSN: 16632818     EISSN: 16632826     Source Type: Journal    
DOI: 10.1159/000271919     Document Type: Article

References (26)

1. Artese R, D'Osvoldo DH, Molocznik I, Benencia H, Oviedo J, Burdman JA, Basso A: Pituitary tumors in adolescent patients. Neurol Res 1998; 20: 415-417. (Pubitemid 28304574)
2. Kane LA, Leinung MC, Scheithauer BW, Bergstrahl EJ, Laws ER Jr, Groover RV, Kovacs K, Horvath E, Zimmerman D: Pituitary adenomas in childhood and adolescence. J Clin Endocrinol Metab 1994; 79: 1135-1140. (Pubitemid 24342261)
3. Abe T, Tara LA, Lüdecke DK: Growth hormone- secreting pituitary adenomas in childhood and adolescence: features and results of transnasal surgery. Neurosurgery 1999; 45: 1-10.
4. Espiner EA, Carter TA, Abbott GD, Wrightson P: Pituitary gigantism in a 31-month-old girl: endocrine studies and successful response to hypophysectomy. J Endocrinol Invest 1981; 4: 445-450. (Pubitemid 12073882)
5. Lu PW, Silink M, Johnston I, Cowell CT, Jimenez M: Pituitary gigantism. Arch Dis Child 1992; 67: 1039-1041.
6. Flitsch J, Lüdecke DK, Stahnke N, Wiebel J, Saeger W: Transsphenoidal surgery for pituitary gigantism and galactorrhea in a 3.5- year-old child. Pituitary 2000; 2: 261-267.
7. Zampieri P, Scanarini M, Sicolo N, Andrioli G, Mingrino S: The acromegaly-gigantism syndrome. Report of four cases treated surgically. Surg Neurol 1983; 498-503. (Pubitemid 14202407)
8. Gelber SJ, Heffez DS, Donohoue PA: Pituitary gigantism caused by growth hormone excess from infancy. J Pediatr 1992; 120: 931-934.
9. Fazekas I, Pasztor E, Slowik F, Balint K, Dobronyi I, Bacsy E, Gyevai A, Peter F, Blatniczky L, Varga I, Glaz E: Pathological and experimental investigations in a case of gigantism. Acta Neuropathol 1993; 85: 167-174. (Pubitemid 23068506)
10. Näntö-Salonen K, Koskinen P, Sonninen P, Toppari J: Suppression of GH secretion in pituitary gigantism by continuous subcutaneous octreotide in a pubertal boy. Acta Paediatr 1999; 88: 29-33. (Pubitemid 29100195)
11. Drimmie FM, MacLennan AC, Nicoll JA, Simpson E, McNeill E, Donaldson MD: Gigantism due to growth hormone excess in a boy with optic glioma. Clin Endocrinol 2000; 53: 535-538.
12. Schoof E, Dörr HG, Kiess W, Lüdecke DK, Freitag E, Zindel V, Rascher W, Dötsch J: Five-year follow-up of a 13-year-old boy with a pituitary adenoma causing gigantism - effect of octreotide therapy. Horm Res 2004; 61: 184-189. (Pubitemid 38437689)
13. Maheshwari HG, Prezant TR, Herman-Bonert V, Shahinian H, Kovacs K, Melmed S: Long-acting peptidomimergic control of gigantism caused by pituitary acidophilic stem cell adenoma. J Clin Endocrinol Metab 2000; 85: 3409-3416.
14. Rix M, Laurberg P, Hoejberg AS, Brock-Jacobsen B: Pegvisomant therapy in pituitary gigantism: successful treatment in a 12-yearold girl. Eur J Endocrinol 2005; 153: 195-201. (Pubitemid 41167475)
15. Ali O, Banerjee S, Kelly DF, Lee PD: Management of type 2 diabetes mellitus associated with pituitary gigantism. Pituitary 2007; 10: 359-364. (Pubitemid 350130582)
16. Goldenberg N, Racine MS, Thomas P, Degnan B, Chandler W, Barkan A: Treatment of pituitary gigantism with the growth hormone receptor antagonist pegvisomant. J Clin Endocrinol Metab 2008; 93: 2953-2956.
17. Van der Lely AJ, Hutson RK, Trainer PJ, Besser GM, Barkan AL, Katznelson L, Klibanski A, Herman-Bonert V, Melmed S, Vance ML, Freda PU, Stewart PM, Friend KE, Clemmons DR, Johannsson G, Stavrou S, Cook DM, Phillips LS, Strasburger CJ, Hackett S, Zib KA, Davis RJ, Scarlett JA, Thorner MO: Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 2001; 358: 1754-1759. (Pubitemid 33152999)
18. Kopchick JJ, Parkinson C, Stevens EC, Trainer PJ: Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly. Endocr Rev 2002; 23: 623-646. (Pubitemid 35191626)
19. Schreiber I, Buchfelder M, Droste M, Forssmann K, Mann K, Saller B, Strasburger CJ: Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study. Eur J Endocrinol 2007; 156: 75-82. (Pubitemid 46553905)
20. Main KM, Sehested A, Feldt-Rasmussen U: Pegvisomant treatment in a 4-year-old girl with neurofibromatosis type 1. Horm Res 2006; 65: 1-5. (Pubitemid 43177310)
21. Müssig K, Gallwitz B, Honegger J, Strasburger CJ, Bidlingmaier M, Machicao F, Bornemann A, Ranke MB, Häring HU, Petersenn S: Pegvisomant treatment in gigantism caused by a growth hormone-secreting giant pituitary adenoma. Exp Clin Endocrinol Diabetes 2007; 115: 198-202. (Pubitemid 46640290)
22. Tanner JM, Whitehouse RH, Cameron N: The method in practice: standards for skeletal maturity and bone age; in Tanner JM, Whitehouse RH, Cameron N (eds): Assessment of Skeletal Maturity and Prediction of Adult Height (TW2 Method), ed 2. San Diego, Academic Press, 1983, pp 9-21.
23. Parkinson C, Trainer PJ: Growth hormone receptor antagonists therapy for acromegaly. Bailleres Best Pract Res Clin Endocrinol Metab 1999; 13: 419-430. (Pubitemid 30312452)
24. Trainer PJ: Lessons from 6 years of GH receptor antagonist therapy for acromegaly. J Endocrinol Invest 2003; 26: 44-52.
25. Colao A, Pivonello R, Auriemma RS, De Martino MC, Bidlingmaier M, Briganti F, Tortora F, Burman P, Kourides IA, Strasburger CJ, Lombardi G: Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect of IGF-1 levels, tumor mass, hypertension and glucose tolerance. Eur J Endocrinol 2006; 154: 467-477.
26. Hodish I, Barman A: Long-term effects of pegvisomant in patients with acromegaly. Nat Clin Pract Endocrinol Metab 2008; 4: 324-332. (Pubitemid 351733473)